Scleroproteins, E.g., Fibroin, Elastin, Silk, Etc. Patents (Class 530/353)
-
Publication number: 20030044899Abstract: The present invention provides isolated laminin 10, methods for making recombinant laminin 10, host cells that express recombinant laminin 10, and methods for using the recombinant laminin 10 to accelerate the healing of injuries to vascular tissue, and to promote cell attachment and migration.Type: ApplicationFiled: December 21, 2001Publication date: March 6, 2003Inventors: Karl Tryggvason, Masayuki Doi, Jill Thyboll
-
Patent number: 6521244Abstract: A body filling agent is formed of a collagen in the form of powder, fiber or gel, and at least one kind of implantable particles selected from a group consisting of implantable polymer and pericardium. A mixture of the collagen and the implantable particles forming the body filling agent is deposited in a body. The collagen is absorbed into the body, but the implantable particles remain in the body as a part of the body.Type: GrantFiled: June 13, 2000Date of Patent: February 18, 2003Inventor: Nozomu Kanesaka
-
Publication number: 20030032089Abstract: An isolated nucleic acid molecule encoding the cocoon silk protein from the black fly, Simulium vittatum. Also provided are the amino acid sequence derived from the cocoon silk, primers used to screen cDNA libraries to promote the building of a complimentary strand of DNA encoding the cocoon silk protein, a transformed microorganism containing cDNA which codes for cocoon silk protein, the amino acid sequence translated from the isolated gene of the cocoon silk (deduced from nucleotide sequence), primers for constructing a segment of recombinant DNA.Type: ApplicationFiled: June 28, 2001Publication date: February 13, 2003Inventors: Fiona F. Hunter, Michael J. Bidochka
-
Patent number: 6489446Abstract: A polypeptide is provided that has a secondary structure characterized by at least three beta-sheet/beta-turn structures, and that is not a naturally occurring fibrous protein. Such polypeptides, illustrated by one modeled on elastin, are useful in prosthesis.Type: GrantFiled: June 29, 1999Date of Patent: December 3, 2002Assignees: HSC Research and Development Limited Partnership, Protein Specialties, Ltd.Inventors: Aser Rothstein, Fred Keeley, Steven Rothstein
-
Publication number: 20020137211Abstract: The present invention provides a method for establishing an expression system of spider dragline silk gene in Bombyx mori. The rate of transformation is about 0.5-1%. In the silk protein produced by the transgenic Bombyx mori obtained by the method of the present invention, the spider dragline silk gene product account for 30% of the total silk proteins.Type: ApplicationFiled: October 4, 2001Publication date: September 26, 2002Applicant: Sichuan University Tianyou Biologic Engineering Co. LTD.Inventors: Tianyan Liu, Huifen Liu, Wei Li, Libin Zhao
-
Patent number: 6440729Abstract: The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 a chain monomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer, or protein constructs having substantially the same structure as the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer.Type: GrantFiled: March 26, 1999Date of Patent: August 27, 2002Assignee: University of Kansas Medical CenterInventors: Billy G. Hudson, Michael P. Sarras, Jr.
-
Patent number: 6432706Abstract: The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 &agr; chain monomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer, or protein constructs having substantially the same structure as the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer.Type: GrantFiled: June 7, 2000Date of Patent: August 13, 2002Assignee: University of Kansas Medical CenterInventors: Billy G. Hudson, Michael P. Sarras, Jr.
-
Publication number: 20020106737Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human SQM2. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding human SQM2. The invention also provides for the use of purified SQM2 and its agonists in the production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of SQM2. Additionally, the invention provides for the use of SQM2 antagonists and inhibitors, including antisense molecules to SQM2 polynucleotides (i.e., gene sequences) in pharmaceutical compositions for the treatment of diseases associated with the expression of SQM2. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts and/or genomic DNA encoding SQM2 and anti-human SQM2 antibodies which specifically bind to SQM2.Type: ApplicationFiled: September 21, 2001Publication date: August 8, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Publication number: 20020086977Abstract: The present invention discloses a method for preparing a hydrophilic porous polymeric material comprising the step of mixing a hydrophilic polymeric material with a hydrophobic material; solvent sintering the surface of the hydrophilic polymeric material with water or an aqueous solution; and removing the hydrophobic material contained within the hydrophilic polymeric material with a massive organic solvent. Thus, the hydrophilic porous polymeric material with high porosity and stable structure is rapidly mass produced.Type: ApplicationFiled: October 19, 2001Publication date: July 4, 2002Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Huey-Min Lai, Chun-Hui Chang, Chun-Jen Liao, Chin-Fu Chen, Kuei-Hung Wu, Yuan-Chia Chang, Yu-Yen Jan, Tsung-Yi Mou
-
Publication number: 20020045735Abstract: The present invention relates to a new method for extraction and purification of cartilage type proteoglycan, and is to provide a method for extraction of crude proteoglycan characterizing to use acid as eluting solvent of cartilage.Type: ApplicationFiled: July 30, 2001Publication date: April 18, 2002Applicant: Kakuhiro Co., Ltd.Inventor: Keiichi Takagaki
-
Patent number: 6372228Abstract: A method is provided for producing elastin or elastin-based materials or tropoelastin materials which have a substantially reduced level of calcification. These materials are typically capable of being formed into a fused layer. The subject method comprises providing unreacted elastin or elastin-based biomaterials or tropoelastin materials, and pretreating the unreacted elastin or elastin-based biomaterials or tropoelastin materials with an aliphatic alcohol prior to reaction thereof. In this way, when the pretreated unreacted elastin or elastin-based biomaterials or tropoelastin materials is reacted subsequently, elastin or elastin-based materials or tropoelastin materials are produced which have a substantially reduced level of calcification as compared with elastin or elastin-based materials or tropoelastin materials produced from non-pretreated counterpart unreacted elastin or elastin-based biomaterials or tropoelastin materials.Type: GrantFiled: December 30, 1997Date of Patent: April 16, 2002Assignees: Providence Health System, Inc.Inventor: Kenton W. Gregory
-
Publication number: 20020038006Abstract: The invention provides two human extracellular matrix proteins (ECMP) and polynucleotides which identify and encode ECMP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of ECMP.Type: ApplicationFiled: April 16, 2001Publication date: March 28, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Neil C. Corley, Karl J. Guegler
-
Patent number: 6361994Abstract: The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 &agr; chain monomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer, or protein constructs having substantially the same structure as the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer.Type: GrantFiled: July 18, 2000Date of Patent: March 26, 2002Assignee: University of Kansas Medical CenterInventors: Billy G. Hudson, Michael P. Sarras, Jr.
-
Patent number: 6358735Abstract: The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 &agr; chain monomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer, or protein constructs having substantially the same structure as the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer.Type: GrantFiled: July 18, 2000Date of Patent: March 19, 2002Assignee: University of Kansas Medical CenterInventors: Billy G. Hudson, Michael P. Sarras, Jr.
-
Publication number: 20020025918Abstract: Novel synthetic lytic and proliferative peptides were designed and constructed to encompass the structural features associated with lytic and proliferative activity. These compounds, along with the human &bgr; fibrin signal peptide share structural and functional properties of the known lytic peptides. These peptides are effective agents in the treatment of microbial infections including gram negative and gram positive bacteria, fungus, virus, yeast, and protozoa, in the lysis of cancer cells, and in the proliferation of fibroblasts and lymphocytes. Additional functions include synergy and use as general adjuvants and in the enhancement of wound healing.Type: ApplicationFiled: July 3, 2001Publication date: February 28, 2002Applicant: Helix BioMedix, Inc.Inventor: Jesse M. Jaynes
-
Publication number: 20020022716Abstract: The present invention provides high throughput screening systems for identifying compounds that modulate the biological activity of a biochemically functional sarcomere. The method can be performed in plurality simultaneously with fluorescence or absorbance readouts.Type: ApplicationFiled: September 26, 2001Publication date: February 21, 2002Inventors: James J. Hartman, Fady Malik, Roman Sakowicz, Jeffrey T. Finer
-
Patent number: 6316221Abstract: A method which enable to provide sufficient amount of insect OBP, and moreover, to produce on a large scale under the condition of physiological activation is proposed. The functional expression of pheromone binding protein from B. mori, whereby it is expressed with Escherichia coli by the pET-22b vector which contains the pe1B signal peptide.Type: GrantFiled: February 24, 1999Date of Patent: November 13, 2001Assignee: Japan as represented by Director General of National Institute of Sericultural and Entomological Science, Ministry of Agriculture Forestry and FisheriesInventors: Walter Soares Leal, Hubert Wojtasek
-
Patent number: 6296850Abstract: Apoptosis-related antigenic compounds comprising an exposed antigenic site having the amino acid sequence SEQ ID NO: 1: Glu Asp Phe Asn Leu Gly Asp Ala Leu Asp 1 5 10 or a functionally equivalent sequence comprising at least the sequence Ala Leu Asp are disclosed.Type: GrantFiled: September 29, 1998Date of Patent: October 2, 2001Assignee: Peviva ABInventors: Viveka Björklund, Bertil Björklund, Peter Björklund, Marius Nap, Frans C. S. Ramaekers, Bert Schutte
-
Patent number: 6274704Abstract: The biologically active peptide of the invention has a number of amino acids of 30 or less, comprises an amino acid sequence described as SEQ ID NO:13 (Tyr Thr Ile Tyr Val Ile Ala Leu) in the sequence listing and has cell adhesion inhibition activity. The peptide of the invention has short length and, therefore, synthesis and handling of the peptide are easy.Type: GrantFiled: September 18, 1997Date of Patent: August 14, 2001Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Fumio Fukai, Takashi Katayama
-
Patent number: 6268169Abstract: The invention relates to novel spider silk protein analogs derived from the amino acid consensus sequence of repeating units found in the natural spider dragline of Nephila clavipes. More specifically, synthetic spider dragline has been produced from E. coli and Bacillus subtilis recombinant expression systems wherein expressions from E. coli is at levels greater than 1 mg full-length polypeptide per gram of cell mass.Type: GrantFiled: December 11, 1995Date of Patent: July 31, 2001Assignee: E. I. du Pont de Nemours and CompanyInventor: Stephen R. Fahnestock
-
Patent number: 6254986Abstract: A method for modifying a protein or polypeptide is disclosed which includes the steps of dispersing a protein or polypeptide in an essentially non-aqueous medium and peracylating the protein or polypeptide with a cyclic anhydride having a carbon chain substituent selected from the group consisting of alkyl and alkenyl groups. Most preferably, the cyclic anhydride is succinic anhydride, although glutaric anhydride may also be employed. Preferably, the step of peracylating the protein or polypeptide is performed in the presence of an acid catalyst, most preferably &rgr;-toluene sulfonic acid. The resultant modified protein or polypeptide may be employed in numerous applications including drug delivery, absorbable sutures, and thermoplastic films and molded articles.Type: GrantFiled: June 14, 2000Date of Patent: July 3, 2001Assignee: Poly-Med, Inc.Inventors: Shalaby W. Shalaby, Jacqueline M. Allan, Joel T. Corbett
-
Patent number: 6232458Abstract: Recombinant tropoelastins and variants of recombinant tropoelastins produced from synthetic polynucleotides, as well as the synthetic polynucleotides themselves are provided. Also provided are cross-linked elastins or elastin-like products prepared from the tropoelastins or variants.Type: GrantFiled: July 24, 1995Date of Patent: May 15, 2001Assignee: The University of SydneyInventors: Anthony Steven Weiss, Stephen Lewis Martin
-
Publication number: 20010001041Abstract: This invention relates to a process by which organic solvent-containing solutions are used in lieu of pure water for the preparation of cartilage extracts and fractions thereof. Different organic solvents have been tested for the preparation of extracts containing biologically active components possessing at least an activity against a matrix metalloprotease (anti-MMP). This invention also relates to a process by which a total liquid extract of shark cartilage composed of molecules having molecular weights less than about 500kDa (0-500 fraction) is purified into two well separated fractions composed of molecules having molecular weights less than about 1 kDa (0-1 fraction) and between about 1 to 500 kDa (1-500 fraction). In order to prevent the formation of aggregates, to improve the dissolution and the stability of active components, sucrose or other stabilizing agents can be added.Type: ApplicationFiled: December 29, 2000Publication date: May 10, 2001Inventors: Eric Dupont, Yves Lachance, Denis Lessard, Serge Auger
-
Patent number: 6184348Abstract: Novel polymers are provided which are produced by recombinant techniques. The polymers are characterized by having a small repeating sequence which provides for strands capable of associating, resulting in useful structural characteristics, where the strands are joined by turns or loops which are flexible and available for interaction with the environment. Specifically, repeating groups of naturally occurring proteins such as silk are modified by introduction of an amino-acid sequence at a site which provides for a turn between strands to provide for readily available oligopeptides capable of interacting with molecules in the environment.Type: GrantFiled: June 7, 1995Date of Patent: February 6, 2001Assignee: Protein Polymer TechnologiesInventors: Franco A. Ferrari, Joseph Cappello
-
Patent number: 6171827Abstract: There is disclosed molecules comprising at least a first moiety having the activity of a procollagen C-propeptide and a second moiety selected from any one of the group of an alien collagen &agr;-chain and non-collagen materials, the first moiety being attached to the second moiety. Also disclosed are collagen molecules, fibrils and fibres comprising a non-natural combination of collagen &agr;-chains, DNA encoding same, expression hosts transformed or transfected with same, transgenic animals and methods of producing a non-natural collagen.Type: GrantFiled: May 7, 1998Date of Patent: January 9, 2001Assignee: The Victoria University of ManchesterInventors: Neil Bulleid, Karl Kadler
-
Patent number: 6140072Abstract: Novel polymers are provided which are produced by recombinant techniques. The polymers are characterized by having a small repeating sequence which provides for strands capable of associating, resulting in useful structural characteristics, where the strands are joined by turns or loops which are flexible and available for interaction with the environment. Specifically, repeating groups of naturally occurring proteins such as silk are modified by introduction of an amino-acid sequence at a site which provides for a turn between strands to provide for readily available oligopeptides capable of interacting with molecules in the environment.Type: GrantFiled: June 7, 1995Date of Patent: October 31, 2000Assignee: Protein Polymer Technologies, Inc.Inventors: Franco A. Ferrari, Joseph Cappello
-
Patent number: 6090915Abstract: An animal collagen or gelatin based crumble, and processes for the preparation of the particulate crumble, are useful in the preparation of collagen or gelatin based compositions. The crumble is prepared by extracting animal collagen from an animal tissue source and combining the collagen with sufficient water to form a composition comprising about 15-45 wt % animal collagen and about 0.01-5 wt % of a stabilizer or preservative. Such a combination of materials can be solidified and then processed into a large particulate format. The large particulate comprises a, regular or amorphous shaped, roughly crumbled or roughly divided, crumble product. The typical particle size of a majority of the crumble is about 0.2-5 cm. The crumble is easily manufactured, packaged, stored, handled and distributed. The crumble can be easily used as is. The material melts easily into a use locus.Type: GrantFiled: October 18, 1996Date of Patent: July 18, 2000Assignee: Hormel Foods CorporationInventor: Richard M. Herreid
-
Patent number: 6034220Abstract: Highly repetitive proteins which are relatively insoluble in water are chemically modified to increase solubility. The protein is reacted with a functionalizing agent to introduce additional polar functionalities and disrupt the order of the protein. The solubility of the protein in water is increased by the chemical modification, while adhesive and surfactant properties are retained.Type: GrantFiled: February 23, 1998Date of Patent: March 7, 2000Assignee: Protein Polymer TechnologiesInventor: Erwin R. Stedronsky
-
Patent number: 6016862Abstract: An animal collagen or gelatin based crumble, and processes for the preparation of the particulate crumble, are useful in the preparation of collagen or gelatin based compositions. The crumble is prepared by extracting animal collagen from an animal tissue source and combining the collagen with sufficient water to form a composition comprising about 15-45 wt % animal collagen and about 0.01-5 wt % of a stabilizer or preservative. Such a combination of materials can be solidified and then processed into a large particulate format. The large particulate comprises a, regular or amorphous shaped, roughly crumbled or roughly divided, crumble product. The typical particle size of a majority of the crumble is about 0.2-5 cm. The crumble is easily manufactured, packaged, stored, handled and distributed. The crumble can be easily used as is. The material melts easily into a use locus.Type: GrantFiled: March 10, 1999Date of Patent: January 25, 2000Assignee: Hormel Foods CorporationInventor: Richard M. Herreid
-
Patent number: 6018030Abstract: Polypeptides comprising repetitive units of amino acids, as well as synthetic genes encoding the subject polypeptides are provided. The subject polypeptides are characterized by comprising repetitive units of amino acids, where the repetitive units are present in naturally occurring proteins, particularly naturally occurring structural proteins. The subject polypeptides find use in a variety of applications, such as structural components of prosthetic devices, synthetic fibers, and the like.Type: GrantFiled: June 7, 1995Date of Patent: January 25, 2000Assignee: Protein Polymer Technologies, Inc.Inventors: Franco A. Ferrari, Charles Richardson, James Chambers, Stuart Causey, Thomas J. Pollock, Joseph Cappello, John W. Crissman
-
Patent number: 5986052Abstract: Link protein and cartilage matrix protein, which are two major components of the extracellular cartilage matrix, have been found to bind to each other. Polypeptide fragments of cartilage matrix protein and link protein are produced. A recombinant fusion polypeptide is prepared containing a fragment of cartilage matrix protein that binds to link protein and a fragment of link protein that binds to cartilage matrix protein. The cartilage matrix protein fragment may bind to collagen and contain the CMP-1 or CMP-2 domain, and the link protein may bind to a complex of hyaluronic acid and proteoglycan. The fragments or fusion polypeptide can be administered for repair of diseased or injured cartilaginous and non-cartilaginous tissue by promoting binding of a complex of proteoglycan and hyaluronic acid to collagen. The fragments or fusion polypeptide can be anchored to the surface of a prosthetic device, implant or tissue graft to promote adherence of tissue and biocompatibility.Type: GrantFiled: June 5, 1995Date of Patent: November 16, 1999Assignee: The General Hospital CorporationInventors: Paul F. Goetinck, M. Mehrdad Tondravi, Francois Binette
-
Patent number: 5969106Abstract: A polypeptide is provided that has a secondary structure characterized by at least three beta-sheet/beta-turn structures, and that is not a naturally occurring fibrous protein. Such polypeptides, illustrated by one modeled on elastin, are useful in prosthesis.Type: GrantFiled: August 7, 1997Date of Patent: October 19, 1999Assignees: The Hospital for Sick Children, Protein Specialties, Ltd.Inventors: Aser Rothstein, Fred W. Keely, Steven J. Rothstein
-
Patent number: 5955578Abstract: A conjugate of a synthetic polypeptide containing RGD or (dR) GD and a biodegradable polymer, such as hyaluronic acid or chondroitin sulfate is disclosed. Methods of making the conjugate and using it to aid wound healing by providing a temporary matrix are disclosed.Type: GrantFiled: June 5, 1995Date of Patent: September 21, 1999Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, James W. Polarek, Marianne P. Petrica, Erkki I. Ruoslahti
-
Patent number: 5948891Abstract: The present invention relates to purified and isolated polynucleotides encoding a polypeptide which specifically bind to a cytoplasmic portion of an integrin. Specifically, the invention provides a FLP-1-encoding polynucleotide and the polypeptide product of the gene. Expression vectors comprising the polynucleotide, antibodies which recognize the polypeptide, hybridomas which secrete the antibodies, and method to identify modulators of interaction of the polypeptide with .beta..sub.7 subunits sequences are also provided.Type: GrantFiled: January 6, 1997Date of Patent: September 7, 1999Assignee: ICOS CorporationInventors: Donald E. Staunton, Edith A. Salot Harris
-
Patent number: 5948428Abstract: The present invention provides pharmaceutical compositions comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. Methods for improving the tissue inductive activity of a morphogenic protein in a mammal using those compositions are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic implants. Methods for inducing local tissue formation from a progenitor cell in a mammal using those devices are also provided. A method for accelerating allograft repair in a mammal using morphogenic devices is provided.Type: GrantFiled: December 6, 1996Date of Patent: September 7, 1999Assignee: Stryker CorporationInventors: John C. Lee, Lee-Chuan C. Yeh
-
Patent number: 5922570Abstract: The present invention relates to purified and isolated polynucleotides encoding a polypeptide which specifically bind to a cytoplasmic portion of an integrin. Specifically, the invention provides a FLP-1-encoding polynucleotide and the polypeptide product of the gene. Expression vectors comprising the polynucleotide, antibodies which recognize the polypeptide, hybridomas which secrete the antibodies, and method to identify modulators of interaction of the polypeptide with .beta..sub.7 subunits sequences are also provided.Type: GrantFiled: January 5, 1996Date of Patent: July 13, 1999Assignee: ICOS CorporationInventors: Donald E. Staunton, Edith Salot Harris
-
Patent number: 5914317Abstract: Recombinant laminin B1k and fragments thereof.Type: GrantFiled: October 23, 1996Date of Patent: June 22, 1999Assignees: The General Hospital Corporation, The State of Oregon Acting By & Thru The State Board . . .Inventors: Robert E. Burgeson, David Wolfe Wagman
-
Patent number: 5883227Abstract: The present invention relates to the diagnosis of multiple sclerosis. More specifically, this invention relates to an assay for detecting antigen(s) associated with multiple sclerosis. The present invention also relates to the generation of hybridomas which produce monoclonal antibodies which are specific for the multiple sclerosis-associated antigens. The present invention's use is in diagnosing multiple sclerosis and in routine follow-up monitoring of multiple sclerosis patients as to disease progression or response to therapy.Type: GrantFiled: October 28, 1996Date of Patent: March 16, 1999Assignees: Molecullar Rx, Inc., Cell Med, Inc.Inventors: Ellis L. Kline, Daniel H. Zimmerman
-
Patent number: 5872209Abstract: The invention relates to novel recombinant substrates for aggrecanase. In one embodiment, this substrate comprises the signal sequence of CD5, the FLAG-epitope for M1 monoclonal antibody detection, the interglobular domain of human aggrecan, the hinge region of human IgG1, the CH2 region of human IgG1 and the CH3 region of human IgG1. DNA sequences encoding the recombinant substrate are also provided, as are vectors and host cells containing said DNA. Various methods are provided for: monitoring aggrecanase activity, detecting new enzymatic cleavage sites, purifying aggrecanase chromatographically, and cloning the aggrecanase cDNA, screening for aggrecanase inhibitors; and for monitoring the onset or progression of osteoarthritis. A diagnostic aid containing the recombinant substrate is also provided.Type: GrantFiled: January 17, 1997Date of Patent: February 16, 1999Assignee: Hoechst AktiengesellschaftInventors: Eckart Bartnik, Bernd Eidenmueller, Frank Buettner, Bruce Caterson, Clare Hughes
-
Patent number: 5824640Abstract: Substances of polypeptide nature are obtainable by extraction with HClO.sub.4 and 3M KCl from animal tissue homogenates. The substances have the characteristics of (a) molecular weights ranging from 10,000 to 50,000 daltons (by polyacrylamide gel electrophoresis); (b) are capable of inducing the formation of antibodies which specifically bind in vivo or in vitro antigens which are present in human tumoral cells, when administered to different animal species; (c) are capable of decreasing or inhibiting pain; (d) induce an effect of cell lysis; and (e) inhibit or slow tumor growth, when administered to humans affected by malignant tumors of different kinds.Type: GrantFiled: March 13, 1995Date of Patent: October 20, 1998Assignee: Zetesis S.p.A.Inventors: Alberto Bartorelli, Angela Turiano
-
Patent number: 5773577Abstract: Polymers are provided comprising protein polymers comprising blocks of repeating units and sequences comprising amino acids, individually or in defined sequences, capable of enzyme catalyzed covalent bond formation for cross-linking, as exemplified by glutamine and/or lysine reactive for FXIII catalyzed isopeptide formation or non-amino acid polymers having side chains comprising such amino acids or sequences, which may be used for preparation of articles of manufacture, particularly cross-linkable compositions. By appropriate choice of the polymer, resorbable implantable polymers may be used in internal applications for mammals as formed objects or depots.Type: GrantFiled: March 2, 1995Date of Patent: June 30, 1998Assignee: Protein Polymer TechnologiesInventor: Joseph Cappello
-
Patent number: 5770697Abstract: Novel polypeptides comprising repetitive units of amino acids, as well as synthetic genes encoding the subject polypeptides are provided. The subject polypeptides are characterized by comprising repetitive units of amino acids, where the repetitive units are present in naturally occurring proteins, particularly naturally occurring structural proteins. The subject polypeptides find use in a variety of applications, such as structural components of prosthetic devices, synthetic fibers, and the like.Type: GrantFiled: June 7, 1995Date of Patent: June 23, 1998Assignee: Protein Polymer Technologies, Inc.Inventors: Franco A. Ferrari, Charles Richardson, James Chambers, Stuart Causey, Thomas J. Pollock, Joseph Cappello, John W. Crissman
-
Patent number: 5763583Abstract: A process for the production of a solubilized protein is disclosed, which is obtained by reducing disulfide bonds in a disulfide bond-containing water-insoluble protein material into mercapto groups and subsequently converting a part or an entire portion thereof into carboxymethyldisulfide groups. In particular, the disclosed process for the production of a solubilized protein which comprises (a) treating a disulfide bond-containing water-insoluble protein material with an aqueous alkaline solution of a reducing agent, and (b) reacting the protein treated by step (a) with thioglycolic acid in the presence of an oxidizing agent under a weakly acidic to a weakly alkaline condition. A process for the production of regenerated protein products, which comprises regenerating disulfide bonds in the solubilized protein, is also disclosed.Type: GrantFiled: October 6, 1995Date of Patent: June 9, 1998Assignee: Kao CorporationInventors: Kozo Arai, Hiroshi Nojiri, Sachio Naito
-
Patent number: 5760004Abstract: Highly repetitive proteins which are relatively insoluble in water are chemically modified to increase solubility. The protein is reacted with a functionalizing agent to introduce additional polar functionalities and disrupt the order of the protein. The solubility of the protein in water is increased by the chemical modification, while adhesive and surfactant properties are retained.Type: GrantFiled: November 21, 1994Date of Patent: June 2, 1998Assignee: Protein Polymer Technologies, Inc.Inventor: Erwin R. Stedronsky
-
Patent number: 5756677Abstract: cDNA clones encoding minor ampullate spidroin proteins (MiSP) are described. The translated amino acid sequence of the cloned cDNA shows that the MiSPs have a structure which exhibits an amino proximal nonrepetitive region, a repetitive portion and a carboxy-proximal nonrepetitive portion. The repetitive portion of the sequence is describable by a generic repeat formula. Comparison of the amino acid sequences derived from the translation with the sequences of short peptides obtained from solubilized minor ampullate spider silk suggests that the nonrepetitive portions of the protein are cleaved from the protein during secretion from the cells synthesizing the spidroins. This comparison also suggests that the minor ampullate spider silk is composed of at least three polypeptides.Type: GrantFiled: June 2, 1995Date of Patent: May 26, 1998Assignee: University of WyomingInventors: Randolph V. Lewis, Mark Colgin
-
Patent number: 5728810Abstract: The present invention is directed to isolated cDNA which codes for spider silk protein or a fragment or variant thereof, a replicable vector containing cDNA which codes for spider silk protein and which is capable of expressing spider silk protein, a transformed cell or microorganism containing cDNA which codes for spider silk protein or a fragment thereof which is capable of expressing spider silk protein and products, such as fibers, which may be manufactured utilizing the recombinant protein of the present invention.Type: GrantFiled: April 19, 1995Date of Patent: March 17, 1998Assignee: University of WyomingInventors: Randolph V. Lewis, Ming Xu, Michael B. Hinman
-
Patent number: 5726040Abstract: A cosmetic composition including a non naturally-occurring extracellular matrix protein in combination with a cosmetic carrier is described. The protein is preferably of human origin and has not been previously cross-linked. The protein is most preferably selected from the group consisting of soluble human procollagen and soluble human tropoelastin. The protein may include at least one additional non-naturally occurring amino acid sequence moiety, the amino acid sequence moiety selected from the group consisting of a hydrophobic sequence, a hydrophilic sequence, and a lysine-rich sequence.A cosmetic composition in which the non naturally-occurring extracellular matrix protein is an isomorphic form of the protein is also described. The isomorph of the protein is preferably selected from the group consisting of elastin isomorphs, collagen isomorphs and fibronectin isomorphs. Most preferably, the isomorphs are of human origin and have not been previously cross-linked.Type: GrantFiled: May 2, 1996Date of Patent: March 10, 1998Inventors: Burt D. Ensley, Matthew Ludmer
-
Patent number: 5705488Abstract: Injectable implant compositions for soft tissue augmentation comprise elastin and collagen and a biocompatible carrier. An injectable implant composition for soft tissue augmentation is derived from the ligamentum nuchae which has been treated to remove non-collagenous and non-elastinous proteins. Methods of making an injectable implant composition for soft tissue augmentation from the ligamentum nuchae are described.Type: GrantFiled: January 22, 1996Date of Patent: January 6, 1998Assignee: Datascope Investment Corp.Inventors: Ernst Janzen, Matthias Johannes Hoekstra, Richard P. Dutrieux
-
Patent number: 5660994Abstract: The invention relates to the identification of insoluble cytoskeletal proteins, or fragments thereof, which are characteristic of the origin of the tissue. The invention relates as well to the method for detecting such proteins by breaking down and solubilizing the protein for immunological detection and quantitation. The method allows detection of tissue lesions or other pathological foci and metastases.Type: GrantFiled: March 1, 1995Date of Patent: August 26, 1997Assignee: Progen Biotechnik GmbHInventors: Gerda Bruder-Heid, Werner Wilhelm Franke
-
Patent number: 5629009Abstract: A composition and method for controlled release of water-soluble proteins comprising a surface-eroding polymer matrix and water-soluble bioactive factors is described. The composition bioerodes in the biological environment of the subject at a controlled rate, thereby releasing the water soluble proteins at a rate which allows them to interact with local cell populations.Type: GrantFiled: August 7, 1996Date of Patent: May 13, 1997Assignee: Massachusetts Institute of TechnologyInventors: Cato T. Laurencin, Paul A. Lucas, Glenn T. Syftestad, Abraham Domb, Julie Glowacki, Robert S. Langer